CATABASIS PHARMACEUTICALS IN's ticker is CATB and the CUSIP is 14875P107. A total of 24 filers reported holding CATABASIS PHARMACEUTICALS IN in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $1,996,000 | -17.4% | 2,494,827 | -1.0% | 0.00% | – |
| Q2 2018 | $2,416,000 | +128.4% | 2,519,315 | +330.9% | 0.00% | – |
| Q1 2018 | $1,058,000 | +27.6% | 584,715 | +5.0% | 0.00% | – |
| Q4 2017 | $829,000 | +15.0% | 556,781 | +63.7% | 0.00% | – |
| Q3 2017 | $721,000 | +113.9% | 340,074 | +43.4% | 0.00% | – |
| Q2 2017 | $337,000 | -42.9% | 237,180 | -35.7% | 0.00% | – |
| Q1 2017 | $590,000 | -27.2% | 368,893 | +64.4% | 0.00% | – |
| Q4 2016 | $810,000 | -41.4% | 224,325 | -0.0% | 0.00% | – |
| Q3 2016 | $1,382,000 | +174.2% | 224,404 | +64.9% | 0.00% | – |
| Q2 2016 | $504,000 | -31.3% | 136,099 | -6.6% | 0.00% | – |
| Q1 2016 | $734,000 | -29.1% | 145,672 | +11.6% | 0.00% | – |
| Q4 2015 | $1,035,000 | -99.4% | 130,495 | -97.2% | 0.00% | -100.0% |
| Q3 2015 | $168,937,000 | +15629.7% | 4,732,472 | +5277.8% | 0.01% | – |
| Q2 2015 | $1,074,000 | – | 88,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 2,857,667 | $4,572,000 | 5.05% |
| Clarus Ventures, LLC | 2,752,488 | $4,404,000 | 3.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 388,030 | $621,000 | 0.12% |
| Rhenman & Partners Asset Management AB | 310,756 | $497,000 | 0.08% |
| BOSTON FAMILY OFFICE LLC | 24,467 | $39,000 | 0.01% |
| OPPENHEIMER & CO INC | 90,000 | $144,000 | 0.00% |
| Alyeska Investment Group, L.P. | 221,281 | $354,000 | 0.00% |
| A.R.T. Advisors, LLC | 46,747 | $74,000 | 0.00% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 101,347 | $162,000 | 0.00% |
| Acrospire Investment Management LLC | 680 | $1,000 | 0.00% |